Economy Watch Live Updates on the Financial Crisis | MORE » | Business Home »

Page 2 of 2   <      

Statement From the Association of Medical Device Reprocessors

Discussion Policy
Comments that include profanity or personal attacks or other inappropriate comments or material will be removed from the site. Additionally, entries that are unsigned or contain "signatures" by someone other than the actual author will be removed. Finally, we will take steps to block users who violate any of our posting standards, terms of use or privacy policies or any other policies governing this site. Please review the full rules governing commentaries and discussions. You are fully responsible for the content that you post.

The Post Does a Disservice to Patients By Instilling Panic Through Outdated or Irrelevant Examples

The problem with The Post article is that it seeks to alarm readers by exaggerating the risks associated with reprocessed devices. The fact is thatthere are far more problems reported for original devices than there are for reprocessed devices.

The article's use of two tragic incidents of children being injured by "reprocessed" devices is a blatant attempt to inflame the reader's passion. However, the fact is that both events occurred because the medical devices in question appear to have been reprocessed outside of the framework of FDA regulation. The Clowes case occurred in England where FDA has no jurisdiction. And the tracheal tubes used in the Van Duyn case were reprocessed by a hospital at a time when hospitals were not fully subject to FDA regulation. It is simply not appropriate for The Post to use either incident to cast doubt upon the safety of commercial reprocessing in the U.S. today. Indeed, The Post failed to point out that tracheal tubes like those used on Sean Van Duyn and air supply tubes like those used on Tony Clowes are apparently not reprocessed by third-party reprocessors in the United States.

The Nation's Third-Party Reprocessors Have a Stellar Safety Record

There is no evidence that third-party, FDA-regulated reprocessing increases the risk faced by patients. In fact, it may be that reprocessing makes medical procedures safer, because if an original device fails when it is first used, it is not reprocessed. And because every reprocessed device is inspected or tested prior to use, the strong likelihood is that the device will again work properly. The same cannot be said for original devices, which are subject only to sample-testing.

Single-Use Label, Not Required by FDA, But Serves to Sell More Original Devices

The Government Accountability Office report to which the article referred found that the "single-use" label is often little more than a marketing tool of the original equipment manufacturer, who has every incentive to use it in order to sell more devices and avoid the costly validation analysis our members must perform prior to reprocessing. Patients should understand that it is the manufacturer's choice to put the single-use label on a product, it is not an FDA requirement. We shared with The Post examples of original equipment manufacturers continuing to label certain devices as being "for single-use," even after these original equipment manufacturers entered into reprocessing agreements with our members. This is compelling evidence that even the original equipment manufacturers know that many "single use" devices can be safely reprocessed.

FDA Has Always Required Hospitals To Report and Identify Adverse Events Attributable to Reprocessed Devices

FDA has always required that hospitals notify the agency when a reprocessed device was involved in adverse events associated with death or serious injury. In April 2001, FDA issued a Guidance for hospitals that emphasized that hospitals should include in their adverse event reports information that specifies whether the device that is the subject of the report was reprocessed. More recently, the Medwatch form was changed so that a box can be checked if a reprocessed device was used, but to say that this information was not tracked prior to last year is inaccurate. AMDR supplied this FDA guidance document to The Post.

FDA Regulation of Reprocessing Prior to 2000 Was Similar to FDA Regulation of Original Equipment

The Post is wrong to say that reprocessing "had little federal oversight" prior to 2000. Except for premarket submissions, FDA has always required reprocessors to meet the same regulatory requirements as the original equipment manufacturers, including registration and medical device listing for the single-use devices that were to be reprocessed; adverse event reporting; reports to FDA of voluntary corrections and removals; compliance with Quality System Regulation; and labeling controls.

Original Equipment Manufacturers Reverse Engineer Devices, Too

When an original equipment manufacturer wishes to introduce to the market an original device, the regulatory process requires, at a minimum, that the device be substantially equivalent to another device that is already legally marketed. To demonstrate this, the original equipment manufacturers often reverse engineer the marketed product to determine exactly how the competing product was made. Just as it does for original equipment, FDA requires that reprocessed devices be as safe and effective as legally marketed devices. Third-party reprocessors hire the same types of engineers to determine how to make their devices equivalent to the original equipment. If these biomedical, mechanical, electrical, and chemical engineers and microbiologists determine that, after reprocessing, a device may not be clean, sterile, and functional, AMDR's members do not reprocess it. In fact, a very small percentage of the various types of "single use" devices on the market are actually reprocessed.

The Post's investigation, which took nearly a year and purports to be based on an examination of "thousands of pages of documents, including FDA records, court filings and internal company reports," confirms what has been known for quite some time -- that there is no evidence to suggest that the use of reprocessed devices increases patient risk.

We welcomed The Post's investigation into the safe practice of reprocessing and cooperated completely. We are deeply disappointed that the investigation failed to compare the safety profile of reprocessed devices to that of the original equipment manufacturers. The Post missed its opportunity to provide a valuable public service, which we believe would have found that reprocessed devices are every bit as safe, if not safer than original devices.

Reprocessing saves valuable health care dollars, which hospitals can use to provide better access to care, more staff, and better technology. Reprocessing eliminates over 900 tons of medical waste per year. The nation's third-party reprocessors are committed to providing safe products at a fraction of the cost. # # #


<       2


More in Business

Time Space Economy

Time Space Economy

Explore economy news through text and photos from around the world.

WashBiz Blog

Local Companies

Post editors and writers keep you informed about the region's business community.

Economy Watch

Economy Watch

Stay updated with the latest breaking news about the financial crisis.

© 2005 Washingtonpost.Newsweek Interactive